$STEK
Stemtech Corp Stock $stek

$stek Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-K Financial Statement

#000168316823002487 Filed on April 17, 2023

Income Statement

Concept	2023 Q2	2022 Q4	2022
Revenue	$1.128M	$1.080M	$4.559M
YoY Change	-11.62%	-17.74%	5.51%
Cost Of Revenue	$246.2K	$327.6K	$1.164M
YoY Change	-37.39%	-26.78%	13.77%
Gross Profit	$881.9K	$752.0K	$3.395M
YoY Change	-0.14%	-13.07%	2.95%
Gross Profit Margin	78.18%	69.66%	74.47%
Selling, General & Admin	$1.736M	$898.2K	$7.371M
YoY Change	7.27%	-56.11%	34.18%
% of Gross Profit	196.82%	119.44%	217.1%
Research & Development	$177.00		$0.00
YoY Change
% of Gross Profit	0.02%		0.0%
Depreciation & Amortization	$153.9K	$117.2K	$447.4K
YoY Change	40.41%	12.32%	4.39%
% of Gross Profit	17.45%	15.59%	13.18%
Operating Expenses	$1.850M	$1.184M	$8.419M
YoY Change	-3.24%	-55.91%
Operating Profit	-$967.6K	-$432.2K	-$5.023M
YoY Change	-5.89%	-76.27%	-252.31%
Interest Expense	$333.0K	-$204.2K	-$7.321M
YoY Change	-101.44%	-119.3%	93.84%
% of Operating Profit
Other Income/Expense, Net	$678.6K	$600.00	-$3.514M
YoY Change	-102.83%	-100.71%	2733.51%
Pretax Income	-$289.0K	-$446.1K	-$8.537M
YoY Change	-98.84%	-47.4%	20.05%
Income Tax	$1.888K	$95.62K	$95.62K
% Of Pretax Income
Net Earnings	-$286.9K	-$518.9K	-$8.545M
YoY Change	-98.85%	-38.19%	20.73%
Net Earnings / Revenue	-25.43%	-48.06%	-187.41%
Basic Earnings Per Share	$0.00		-$0.19
Diluted Earnings Per Share	$0.00	-$0.01	-$0.19
COMMON SHARES
Basic Shares Outstanding	61.14M shares	48.63M shares	46.01M shares
Diluted Shares Outstanding	91.77M shares		46.01M shares

Balance Sheet

Concept	2023 Q2	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$283.9K	$132.5K	$132.5K
YoY Change	-28.98%	-84.0%	-84.0%
Cash & Equivalents	$283.9K	$132.5K
Short-Term Investments
Other Short-Term Assets	$231.2K	$287.1K	$287.1K
YoY Change	4.85%	-11.59%	-11.59%
Inventory	$225.7K	$158.1K	$158.1K
Prepaid Expenses
Receivables	$23.17K	$34.77K	$34.77K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$764.0K	$612.4K	$612.4K
YoY Change	-9.64%	-61.73%	-61.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$23.13K	$27.30K	$170.1K
YoY Change	-24.58%	-17.7%	-17.93%
Goodwill	$467.4K	$467.4K
YoY Change	0.0%	0.0%
Intangibles	$3.012M	$2.994M
YoY Change	-5.87%	-12.11%
Long-Term Investments	$23.68K	$23.07K	$23.07K
YoY Change	-18.43%	-40.37%	-40.37%
Other Assets
YoY Change
Total Long-Term Assets	$3.638M	$3.655M	$3.655M
YoY Change	-6.07%	-11.3%	-11.3%
TOTAL ASSETS
Total Short-Term Assets	$764.0K	$612.4K	$612.4K
Total Long-Term Assets	$3.638M	$3.655M	$3.655M
Total Assets	$4.402M	$4.267M	$4.267M
YoY Change	-6.71%	-25.4%	-25.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.131M	$3.397M	$3.397M
YoY Change	-19.01%	-16.15%	-16.15%
Accrued Expenses	$106.6K	$119.1K	$119.1K
YoY Change	63.11%	113.58%	113.58%
Deferred Revenue
YoY Change
Short-Term Debt	$2.419M	$1.143M	$1.143M
YoY Change	35.37%	8.28%	8.28%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.710M	$7.416M	$7.416M
YoY Change	-82.87%	-21.0%	-21.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$2.420K	$23.07K	$23.07K
YoY Change	-97.07%	-80.62%	-80.62%
Total Long-Term Liabilities	$2.420K	$23.07K	$23.07K
YoY Change	-98.49%	-93.19%	-93.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.710M	$7.416M	$7.416M
Total Long-Term Liabilities	$2.420K	$23.07K	$23.07K
Total Liabilities	$5.712M	$7.439M	$6.701M
YoY Change	-82.94%	-23.51%	-26.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.15M	-$21.63M
YoY Change	-37.26%	65.3%
Common Stock	$96.32K	$19.44M
YoY Change	-99.1%	91.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$568.0K	-$2.434M	-$2.434M
YoY Change
Total Liabilities & Shareholders Equity	$4.402M	$4.267M	$4.267M
YoY Change	-6.71%	-25.4%	-25.4%

Cashflow Statement

Concept	2023 Q2	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$286.9K	-$518.9K	-$8.545M
YoY Change	-98.85%	-38.19%	20.73%
Depreciation, Depletion And Amortization	$153.9K	$117.2K	$447.4K
YoY Change	40.41%	12.32%	4.39%
Cash From Operating Activities	-$324.0K	-$240.8K	-$1.217M
YoY Change	-51.19%	-77.5%	-36.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	241.4K	-176.0K	$338.7K
YoY Change	30.89%	-133.56%	-87.11%
NET CHANGE
Cash From Operating Activities	-324.0K	-240.8K	-$1.217M
Cash From Investing Activities
Cash From Financing Activities	241.4K	-176.0K	$338.7K
Net Change In Cash	-82.63K	-416.8K	-$695.7K
YoY Change	-82.76%	-23.8%
FREE CASH FLOW
Cash From Operating Activities	-$324.0K	-$240.8K	-$1.217M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001511820
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2021	GNTW	Effect Of Reverse Merger Transaction Value EffectOfReverseMergerTransactionValue		usd
CY2022	GNTW	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative		usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	333-172172
CY2022	dei	Entity Registrant Name EntityRegistrantName	STEMTECH CORPORATION
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2151440
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	10370 USA Today Way
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Miramar
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33025
CY2022	dei	City Area Code CityAreaCode	(954)
CY2022	dei	Local Phone Number LocalPhoneNumber	715-6000
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1683169	usd
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61136808	shares
CY2022	dei	Auditor Firm AuditorFirmId	76
CY2022	dei	Auditor Name AuditorName	Turner, Stone & Company, LLP
CY2022	dei	Auditor Location AuditorLocation	Dallas, Texas
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132487	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	828206	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	34767	usd
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	10720	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	158053	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	436405	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	287063	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	324708	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	612370	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1600039	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	27296	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33168	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2994000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3406714	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	23065	usd
CY2021Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	38692	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	142801	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	174100	usd
CY2022Q4	us-gaap	Goodwill Goodwill	467409	usd
CY2021Q4	us-gaap	Goodwill Goodwill	467409	usd
CY2022Q4	us-gaap	Assets Assets	4266941	usd
CY2021Q4	us-gaap	Assets Assets	5720122	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3396543	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4050798	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	119065	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	55745	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	446246	usd
CY2021Q4	us-gaap	Notes Payable Current NotesPayableCurrent	453123	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	482885	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	602787	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	39170	usd
CY2022Q4	GNTW	Factoring Liability FactoringLiability	214249	usd
CY2021Q4	GNTW	Factoring Liability FactoringLiability	0	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2717633	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	4224585	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7415791	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9387038	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	219465	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23068	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119065	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7438859	usd
CY2021Q4	us-gaap	Liabilities Liabilities	9725568	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53442147	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53442147	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44685673	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44685673	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	53442	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	44685	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	19391400	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10116296	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-247760	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-430255	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-21631241	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-13086318	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2434159	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3355592	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-737759	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	-649854	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3171918	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4266941	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5720122	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4559399	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4321245	usd
CY2022	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1100903	usd
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	1011270	usd
CY2022	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	63115	usd
CY2021	us-gaap	Cost Depreciation Amortization And Depletion CostDepreciationAmortizationAndDepletion	11890	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1164018	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1023160	usd
CY2022	us-gaap	Gross Profit GrossProfit	3395381	usd
CY2021	us-gaap	Gross Profit GrossProfit	3298085	usd
CY2022	GNTW	Commission Expenses CommissionExpenses	1047400	usd
CY2021	GNTW	Commission Expenses CommissionExpenses	1014721	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	533397	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	739855	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6837964	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4753780	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	8418761	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	6508356	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5023380	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3210271	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-3223271	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	4553372	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	4097843	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	8330201	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7928	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-124009	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3799356	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3513830	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3900838	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8537210	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7111109	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	95618	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8632828	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-7111109	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-87905	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-33646	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8544923	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7077463	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46014138	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35311381	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46014138	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35311381	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8544923	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7077463	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-182495	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	19505	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8362428	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7096968	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1267996	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	789173	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	242000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	462519	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	363479	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-19505	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-33646	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-7077463	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4005446	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	439053	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3557132	usd
CY2022	GNTW	Stock Issued For Cash StockIssuedForCash	100002	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	828000	usd
CY2022	GNTW	Stock Issued During Period Value Of Loan Extension StockIssuedDuringPeriodValueOfLoanExtension	4159674	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	182495	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-87905	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8544923	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3171918	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-8632828	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-7111109	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	447386	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	428586	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1378	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-102325	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3996187	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1031173	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2428539	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	602787	usd
CY2022	GNTW	Amortization Due To Conversionredemptions AmortizationDueToConversionredemptions	1457542	usd
CY2021	GNTW	Amortization Due To Conversionredemptions AmortizationDueToConversionredemptions	0	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-3223271	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	4553372	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3799356	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0	usd
CY2021	GNTW	Noncash Interest Expense From Issuance On Debt Derivative NoncashInterestExpenseFromIssuanceOnDebtDerivative	6816739	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24047	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15102	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-278352	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	237778	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37645	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	109122	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-0	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-8053	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-683058	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1217832	usd
CY2022	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	-15627	usd
CY2021	us-gaap	Increase Decrease In Long Term Receivables Current IncreaseDecreaseInLongTermReceivablesCurrent	19818	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	39170	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1216948	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1914093	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	611266	usd
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3321969	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	586783	usd
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	658230	usd
CY2022	GNTW	Net Proceeds From Factoring Arrangement NetProceedsFromFactoringArrangement	214249	usd
CY2021	GNTW	Net Proceeds From Factoring Arrangement NetProceedsFromFactoringArrangement	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	100002	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2021	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-35000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	338734	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2628739	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	182495	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-19505	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-695719	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	695141	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	828206	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	133065	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132487	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	828206	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	36205	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	11389	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	GNTW	Operating Leases Supplemental Cash Flow OperatingLeasesSupplementalCashFlow	0	usd
CY2021	GNTW	Operating Leases Supplemental Cash Flow OperatingLeasesSupplementalCashFlow	187734	usd
CY2022	GNTW	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	828000	usd
CY2021	GNTW	Issuance Of Common Stock For Conversion Of Debt IssuanceOfCommonStockForConversionOfDebt	0	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	200000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	462519	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_804_eus-gaap--NatureOfOperations_zdFZeJgJpQbc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1 – <span id="xdx_828_z9yGvgsYojt3">Organization and Basis of Presentation</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stemtech Corporation and its Subsidiaries (collectively, the “<b>Company</b>”) was incorporated in the State of Nevada, USA on September 4, 2009 under the previous name Globe Net Wireless Corp. On November 19, 2021, the Company adopted an Amendment to its Articles changing the name of the Corporation to Stemtech Corporation in the state of Nevada, and on April 14, 2022, FINRA gave final approval for said name change, as evidenced by the 8-K filed that date. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes our products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Company’s subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, OraStem® (Oral Health Care), and D-Fuze™ (Electromagnetic Frequency Blocker). Cellect One™ Rapid Renew Stem Cell Peptide Night Cream.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 19, 2021, Stemtech Corporation (“<b>Stemtech</b>”), a Delaware corporation, entered into a Merger Agreement (the “<b>Merger Agreement</b>”) with Globe Net Wireless Corp. (“<b>Globe Net</b>” or “<b>GNTW</b>”). The merger was accounted for as a reverse acquisition and recapitalization in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805, <i>Business Combinations</i>. Management evaluated the guidance contained in ASC 805 with respect to the identification of the acquirer in the merger and concluded, based on a consideration of the pertinent facts and circumstances, that Stemtech acquired Globe Net for financial accounting purposes. On November 9, 2021, the Company changed its fiscal year end from a fiscal year end of August 31 to a calendar year end of December 31.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of Stemtech (Parent) and its nine (9) subsidiaries:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">1) Stemtech HealthSciences Corp (U.S.A.) (“Stemtech HealthSciences”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">2) Stemtech Canada, Inc. (“Canada”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">3) Stemtech Health Sciences S. de R.L. de C.V. (“Mexico”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">4) Stemtech Services SARL de C.V. (Mexico) (“Stemtech Mexico”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">5) Stemtech Malaysia Holdings Sdn. Bhd. (“Malaysia Holdings”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">6) Stemtech Malaysia Sdn. Bhd. (“Malaysia”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">7) Stemtech Taiwan Holding, Inc. (“Taiwan”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">8) Tecrecel S.A. (“Ecuador”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">9) Food & Health Tech Foodhealth SA (“Ecuador FHTFH”)</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	GNTW	Working Capital Deficiency WorkingCapitalDeficiency	6800000	usd
CY2021Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	186746	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	158053	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	436405	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zlyD0lznlLMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span id="xdx_866_zmrcGReWiWPj">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3010875	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3800000	shares
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	103297	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	249659	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	54756	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	929131	usd
CY2021Q4	us-gaap	Notes Payable NotesPayable	1275375	usd
CY2018Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	2000000	shares
CY2018Q2	us-gaap	Bankruptcy Claims Amount Paid To Settle Claims BankruptcyClaimsAmountPaidToSettleClaims	400000	usd
CY2018Q2	us-gaap	Notes Payable NotesPayable	4000000	usd
CY2018Q2	GNTW	Percentage Of Issued And Outstanding PercentageOfIssuedAndOutstanding	1	pure
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1918200	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	2994000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	85629	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	105673	usd
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	187734	usd
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	187734	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	90450	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	63851	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	154301	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12168	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	142133	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	85629	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	105673	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-495637	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-955027	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-423798	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-462526	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	95618	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2020Q4	GNTW	Derivative Liabilities1 DerivativeLiabilities1	0	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	8777957	usd
CY2021	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	-4553372	usd
CY2021Q4	GNTW	Derivative Liabilities1 DerivativeLiabilities1	4224585	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues	5366289	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Settlements FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements	-10096512	usd
CY2022	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Period Increase Decrease FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationPeriodIncreaseDecrease	3223271	usd
CY2022Q4	GNTW	Derivative Liabilities1 DerivativeLiabilities1	2717633	usd
CY2022	GNTW	Proceeds From Factoring Liability ProceedsFromFactoringLiability	528984	usd
CY2022Q4	GNTW	Factoring Liability Gross FactoringLiabilityGross	292636	usd
CY2021Q4	GNTW	Factoring Liability FactoringLiability	0	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6061667	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	363479	usd
CY2022	us-gaap	Revenues Revenues	4559399	usd
CY2021	us-gaap	Revenues Revenues	4321245	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1164018	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1023160	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	8418761	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	6508356	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5023380	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-3210271	usd
CY2022Q4	us-gaap	Assets Assets	4266941	usd
CY2021Q4	us-gaap	Assets Assets	5720122	usd
CY2018Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	150000	usd
CY2019Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	267000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd
CY2021Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	267000	usd
CY2020Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	32000	usd
CY2022Q4	us-gaap	Litigation Reserve LitigationReserve	6665	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8537210	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7111109	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8537210	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7111109	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1792814	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1493333	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2697747	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2984299	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	110120	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-73413	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6132841	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4369537	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1664597	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	732868	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-83111	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-88159	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1986	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-209	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	140	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7712132	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5014385	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7712132	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5014385	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24400000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	20600000	usd

Files In Submission

Name	View Source	Status
gntw-20221231_cal.xml	Edgar Link	unprocessable
gntw-20221231_lab.xml	Edgar Link	unprocessable
0001683168-23-002487-index-headers.html	Edgar Link	pending
0001683168-23-002487-index.html	Edgar Link	pending
0001683168-23-002487.txt	Edgar Link	pending
0001683168-23-002487-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gntw-20221231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
gntw-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stemtechlogo.jpg	Edgar Link	pending
stemtech_ex2100.htm	Edgar Link	pending
stemtech_ex3100.htm	Edgar Link	pending
stemtech_ex3200.htm	Edgar Link	pending
stemtech_i10k-123122.htm	Edgar Link	pending
stemtech_i10k-123122_htm.xml	Edgar Link	completed
gntw-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STEK
Stemtech Corp Stock $stek

2023 Q2 Form 10-K Financial Statement

#000168316823002487 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK Stemtech Corp Stock $stek

2023 Q2 Form 10-K Financial Statement

#000168316823002487 Filed on April 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STEK
Stemtech Corp Stock $stek